OBJECTIVES: Only recently, new risk factors to explain @entity731 have been identified. One of the most important clinical manifestations of @entity731 is @entity712 . Our study was aimed at investigating @entity1851 ( @entity1851 ), a marker of systemic @entity32 , in the context of @entity712 , and to determine its usefulness in predicting the need for readmission in @entity1 with @entity712 and their degree of improvement. DESIGN: We studied @entity1 admitted to our hospital due to @entity712 , independent of the cause. @entity1851 levels were measured with a sensitive standard assay on a Nephelometer analyser. @entity1 were classified on admission and discharge following New York Heart Association (NYHA) functional criteria; left ejection fraction was also determined by transthoracic echocardiography. @entity1 presenting clear sources of @entity281 or inflammatory disease were excluded. Our control group consisted of @entity1 admitted for @entity1163 . Each @entity1 was followed up through a computer system controlling admissions to and discharge from the hospital, for a period of 18 months after initial admission. End points considered were NYHA functional class on discharge, readmission and death. RESULTS: We studied prospectively 76 @entity1 with a mean age of 73.5+/-11 [95% confidence interval (CI) 71.2-75.8]; 44 were male (58%) and 32 female (42%). The mean @entity1851 level in @entity1 with @entity712 was 3.94+/-5.87 (95% CI, 1.26-7.60), while in 15 @entity1 with @entity1163 it was 0.84+/-1.95 (95% CI, 0.96-2.94) (P=0.0007). The principal causes of @entity712 included @entity384 due to @entity453 (30%), @entity340 (28%) and @entity712 secondary to @entity101 (25%). The mean left ejection fraction adequately measured in 72 (95%) @entity1 was 50.41+/-9.88 (95% CI, 41.20-59.65). We observed a trend of higher @entity1851 levels in relation to ejection fractions below 35%: 7.50+/-9.88 vs. 3.75+/-4.57, (P=0.09). Our results showed that on discharge @entity1851 levels increased in relation to NYHA class: I: 0.74+/-0.69; II: 3.78+/-3.76; III: 7.4+/-8.65; IV: 12.2+/-15.27 (P<0.05). On follow-up of each @entity1 for 18 months, 32 (43%) were readmitted due to deterioration of their heart condition. For @entity1 who were readmitted, those presenting @entity1851 levels >0.9 mg/dl were identified as candidates for earlier hospitalisation than those with levels below 0.9 mg/dl (P=0.02) RR=1.43. In logistic-regression analysis the only group of tested variables predicting readmission were levels of @entity1851 , NYHA class and plasmatic K on discharge and left ventricle ejection fraction. Analysis of covariates yields @entity1851 levels as being an independent predictor of readmission. CONCLUSIONS: An inflammatory response is present in deteriorating @entity712 . We observed higher @entity1851 levels in @entity1 with higher NYHA functional class, perhaps signalling a poor therapeutic response. Higher @entity1851 levels were also related to higher rates of readmission and mortality and it could be an independent marker of improvement and readmission in @entity712 .

XXXX as a predictor of improvement and readmission in @entity712 .

@entity1 :: ('9606', 'Species') :: ['patients', 'Patients', 'patient'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity384 :: ('MESH:D002311', 'Disease') :: ['dilated cardiomyopathy'] @entity1163 :: ('MESH:D013575', 'Disease') :: ['syncope'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary arterial disease'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis', 'atherosclerotic disease'] @entity340 :: ('MESH:D006349', 'Disease') :: ['valvular disease'] @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein', 'CRP']
@entity1851 :: (1401,Gene) :: ['C-reactive protein']
